Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.76 |
| ▸ | CES1 | P23141 | 3/20 | 0.76 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28201061 | 1.00 | CES2 (0.76) | CES2CES1SRCCYP2D6LMNA | |
| SCHEMBL234580 | 1.00 | CES2 (0.76) | CES2CES1SRCCYP2D6LMNA | |
| SCHEMBL5899350 | 1.00 | CES2 (0.76) | CES2CES1SRCCYP2D6LMNA | |
| Ammonia Solution, Strong SCHEMBL38660268 | 0.97 | CES2 (0.73) | CES2CES1SRCCYP2D6LMNA | |
| Hydrochloric Acid SCHEMBL7037834 | 0.97 | CES2 (0.73) | CES2CES1SRCCYP2D6LMNA | |
| Methane SCHEMBL6115781 | 0.97 | CES2 (0.73) | CES2CES1SRCCYP2D6LMNA | |
| Alcohol SCHEMBL29064519 | 0.89 | CES2 (0.61) | CES2CES1SRCCYP2D6LMNA | |
| SCHEMBL5820145 | 0.86 | CES2 (0.73) | CES2CES1SRCCYP2D6LMNA | |
| SCHEMBL7437238 | 0.85 | PTGS2 (0.61) | CES2CES1SRCCYP2D6CYP1A2 | |
| SCHEMBL4973413 | 0.84 | CES2 (0.77) | CES2CES1SRCCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | claimed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | disclosed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007126258-A1 | THE METHOD OF MAKING OPTICALLY ACTIVE 2-HALO-2-(N-SUBSTITUTED PHENYL)ACETIC ACID ESTERS AND 2-HALO-2-(N-SUBSTITUTED PHENYL)ACETIC ACIDS BY ENZYMATIC METHOD | ENZYTECH, LTD (KR) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | disclosed |
| US-7084140-B2 | Arylglycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-01 | — | — | US | disclosed |
| US-20030092704-A1 | Novel arylglycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6498162-B1 | TREATING INFLAMMATORY AND ALLERGIC DISEASES OF RESPIRATORY TRACT AND DISEASES OF CENTRAL NERVOUS SYSTEM | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-24 | — | — | US | disclosed |
| US-6251909-B1 | Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds | BOEHRINGER INGELHEIM KG (DE) | 2001-06-26 | — | — | US | disclosed |
| US-6124296-A | NEUROKININ (TACHYKININ) ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 2000-09-26 | — | — | US | disclosed |
| US-5801274-A | N- mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof as antihypertensives | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-09-01 | — | — | US | disclosed |
| US-5591891-A | PEPTIDASE INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1997-01-07 | — | — | US | disclosed |
| WO-1994017036-A1 | S-LIPOPHILIC ALIPHATIC CARBONYL [N-MERCAPTOACYL-(AMINO ACID OR PEPTIDE)] COMPOUNDS AS ANTIHYPERTENSIVE AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1994-08-04 | — | — | WO | disclosed |
| EP-0595878-A1 | ACYLMERCAPTOALKANOYLDIPEPTIDES, METHODS OF PREPARATION AND THEIR THERAPEUTIC USE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1994-05-11 | — | — | EP | disclosed |
| WO-1993002099-A1 | ACYLMERCAPTOALKANOYLDIPEPTIDES, METHODS OF PREPARATION AND THEIR THERAPEUTIC USE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1993-02-04 | — | — | WO | disclosed |
| EP-0524553-A1 | Acylmercaptoalkanoyldipeptides, methods of preparation and their therapeutic use | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | CES2 1677/4885CES1 213/4885SRC 4485/4885 |
| US-20030092704-A1 | Novel arylglycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds | GCGR, NGLY1, CCKAR | CES2 1591/4885CES1 1684/4885SRC 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.